Comparing Adagio Medical (NASDAQ:ADGM) & NeuroMetrix (NASDAQ:NURO)

Insider and Institutional Ownership

48.1% of Adagio Medical shares are held by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are held by institutional investors. 53.5% of Adagio Medical shares are held by company insiders. Comparatively, 7.3% of NeuroMetrix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Adagio Medical and NeuroMetrix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$266,000.00	57.83	-$2.13 million	N/A	N/A
NeuroMetrix	$3.77 million	2.40	-$6.53 million	($4.59)	-0.96

Adagio Medical has higher earnings, but lower revenue than NeuroMetrix.

Risk and Volatility

Adagio Medical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Profitability

This table compares Adagio Medical and NeuroMetrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	160.59%	40.99%
NeuroMetrix	-203.71%	-42.56%	-39.26%

Summary

Adagio Medical beats NeuroMetrix on 7 of the 9 factors compared between the two stocks.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.